Pablo Corral MD

🏃🏻🌊🌅😍

👉Managing Dyslipidemia in 2025: The Era of Precision Lipidology ☝️As we move through 2025, dyslipidemia management has clearly evolved beyond the traditional statin + ezetimibe approach. ☝️We now have an expanding armamentarium of targeted therapies addressing…

☝️No estimate of the apoB lipoprotein-related risk of CVD is complete without measurement of both apoB and Lp(a) ApoB is the true core marker of atherogenic particle burden, and Lp(a) is an independent, non-negotiable player in cardiovascular risk. ✅ ApoB reflects the number…

🤔If high LDL cholesterol is so dangerous… why doesn’t it hurt? ☝️Because evolution doesn’t care if you drop dead after you’ve reproduced. 👉LDL cholesterol is a silent killer—causal, cumulative, and completely asymptomatic. You won’t feel your arteries clogging. You won’t…

👉Aspirin in primary prevention? Maybe not for everyone. But definitely worth reconsidering for those with elevated Lp(a). This compelling article in The American Journal of Medicine challenges the current dogma: Lipoprotein(a) may redefine aspirin’s role in cardiovascular…

False!

🚨 Coming soon in @ATHjournal ! A powerful new review explores the link between adipose tissue dysfunction and atherosclerosis, shedding light on innovative therapies. This comprehensive review explores the complex interplay between adipose tissue dysfunction and…

🚨 Late-Breaking Science from Argentina at ESC 2025! 🇦🇷 We are immensely proud and deeply honored to announce that our work “GAELp(a): National Registry on Lp(a) and Cardiovascular Risk in Argentina” has been selected as part of the Late-Breaking Clinical Science: Lipids and…

🤩Fantastic lecture by Rob Hegele at @PCSK9Forum pcsk9forum.org/angptl3-a-chol…

🧬 A New Era in Lipid Management? ANGPTL3 as a Game-Changer A great review by Fukami & Oike (J Atheroscler Thromb, 2025) explores the evolving therapeutic landscape targeting ANGPTL3, a key regulator of lipid metabolism. 1️⃣ ANGPTL3 inhibition lowers LDL-C and triglycerides…

☝️Effect of Lipid-lowering Therapies on Lp(a) Levels: A Comprehensive Meta-analysis of RCTs ☝️New evidence just published in @ATHjournal ! 👉This comprehensive meta-analysis of 147 RCTs involving over 145,000 participants confirms that most currently available lipid-lowering…

☝️A paradigm shift in cardiovascular prevention! 👉The latest European Heart Journal State-of-the-Art Review explores the transformative role of gene therapy and genome editing in managing lipoprotein disorders. 👉From PCSK9 base editing to Lp(a) siRNA silencing, the future may…

😍It was a true honor and pleasure to share an entire scientific journey at the Heart Revolution Summit 2025 with Anne Tybjærg-Hansen and @BNordestgaard — two of the most brilliant and generous figures in cardiovascular prevention. Their intellect is matched only by their…

Con los líderes mundiales en aterosclerosis. ⁦@drpablocorral⁩ ⁦@BNordestgaard⁩

A must-read in the field of cardiovascular prevention: “Residual cardiovascular risk beyond LDL-C: inflammation, remnant cholesterol, and lipoprotein(a)” by Anders Wulff and Prof. Børge Nordestgaard, just published in the European Heart Journal (2025). This editorial…

🧬 ApoB Conformation and LDL Atherogenicity 👉This paper delves into how specific conformational changes in apolipoprotein B-100 impact LDL particle behavior — particularly its binding affinity to arterial wall proteoglycans. These structural transitions increase LDL retention…

📢 Hot off the press in @LipidJournal: LDL-C management just got clearer: “Lower for longer is better.” This new guidance from the National Lipid Association brings no-nonsense, risk-based recommendations for real-world practice. ✅ LDL-C is causal ✅ Lowering it reduces events…

☝️Must-read for lipidologists and cardiometabolic specialists This new State-of-the-Art Review in JACC outlines the future of triglyceride-lowering therapy beyond statins. 👉ApoCIII, ANGPTL3/4 inhibitors and FGF-21 analogues show powerful effects in reducing triglycerides and…

I certainly have to agree with my colleague and friend Pablo that this is an amazing document - Roughly 1.4 billion individuals worldwide are exposed to elevated Lp(a) and the vast majority of them do not know that they are living with this condition and an increased ASCVD risk -…